Nicotinamide Phosphoribosyltransferase Inhibitor as a Novel Payload for Antibody–Drug Conjugates

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1FDA Approval: Gemtuzumab Ozogamicin for the Treatment of Adults with Newly Diagnosed CD33-Positive Acute Myeloid Leukemia2018 · 203 citations
2. 2The clinical potential of inotuzumab ozogamicin in relapsed and refractory acute lymphocytic leukemia2015 · 30 citations
3. 3The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor2007 · 295 citations
4. 4Antibody-Maytansinoid Conjugates Are Activated in Targeted Cancer Cells by Lysosomal Degradation and Linker-Dependent Intracellular Processing2006 · 576 citations
5. 5Structure based design of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors from a phenotypic screen2017 · 17 citations